EQT on the sale of 6% of Galderma’s share capital: Homburger and NKF

On September 3, 2024, Sunshine SwissCo (a consortium led by EQT, advised by Homburger), the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte (all acting as the sellers) announced the launch of an accelerated bookbuilding process to professional investors in Switzerland and to qualified investors outside Switzerland, which lead to the successful placement of 14,273,859 shares in Galderma Group (Galderma) at a price of CHF 75 per share (the Placement), raising a total of ca. CHF 1.07 bn in total. Niederer Kraft Frey represented the banking syndicate in the transaction, consisting of Goldman Sachs, Morgan Stanley and UBS.

Homburger’s team

Homburger acted as transaction counsel to EQT. The Homburger team was led by capital markets corporate / M&A partner Frank Gerhard (pictured left) and included Lorenzo Togni (corporate / M&A, capital markets), Estelle Piccard, Simone Schmid and Héloïse de Jamblinne (all corporate / M&A), Micha Fankhauser (financial market regulation) as well as Stefan Oesterhelt (tax).

NKF team

The NKF team was led by capital markets partner Deirdre Ni Annrachain (pictured right).

About the transaction

The sellers will remain shareholders of 61.21% of the share capital of Galderma. EQT’s representation on the Board of Directors of Galderma remains unchanged as a result of the Placement. Such Placement will broaden Galderma’s shareholder base and free float. In connection therewith, the Sellers have agreed to a 90-day lock-up period, subject to certain customary exceptions, with respect to their remaining holding in Galderma. The placement is expected to be settled on September 6, 2024. Following the Placement, no changes to the Galderma board of directors and its governance are envisioned.